Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
18.10
-0.32 (-1.74%)
At close: Aug 14, 2026, 4:00 PM EDT
17.78
-0.32 (-1.77%)
After-hours: Aug 14, 2026, 7:34 PM EDT
Sarepta Therapeutics Employees
Sarepta Therapeutics had 835 employees as of December 31, 2025. The number of employees decreased by 537 or -39.14% compared to the previous year.
Employees
835
Change (1Y)
-537
Growth (1Y)
-39.14%
Revenue / Employee
$2,364,484
Profits / Employee
-$163,743
Market Cap
1.91B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 835 | -537 | -39.14% |
| Dec 31, 2024 | 1,372 | 58 | 4.41% |
| Dec 31, 2023 | 1,314 | 152 | 13.08% |
| Dec 31, 2022 | 1,162 | 322 | 38.33% |
| Dec 31, 2021 | 840 | -26 | -3.00% |
| Dec 31, 2020 | 866 | 123 | 16.55% |
| Dec 31, 2019 | 743 | 244 | 48.90% |
| Dec 31, 2018 | 499 | 244 | 95.69% |
| Dec 31, 2017 | 255 | 58 | 29.44% |
| Dec 31, 2016 | 197 | -73 | -27.04% |
| Dec 31, 2015 | 270 | 66 | 32.35% |
| Dec 31, 2014 | 204 | 58 | 39.73% |
| Dec 31, 2013 | 146 | 43 | 41.75% |
| Dec 31, 2012 | 103 | 5 | 5.10% |
| Dec 31, 2011 | 98 | 0 | - |
| Dec 31, 2010 | 98 | 35 | 55.56% |
| Dec 31, 2009 | 63 | -20 | -24.10% |
| Dec 31, 2008 | 83 | -42 | -33.60% |
| Dec 31, 2007 | 125 | 8 | 6.84% |
| Dec 31, 2006 | 117 | -6 | -4.88% |
| Dec 31, 2005 | 123 | 11 | 9.82% |
| Dec 31, 2004 | 112 | 6 | 5.66% |
| Dec 31, 2003 | 106 | 17 | 19.10% |
| Dec 31, 2002 | 89 | 4 | 4.71% |
| Dec 31, 2001 | 85 | 14 | 19.72% |
| Dec 31, 2000 | 71 | 15 | 26.79% |
| Dec 31, 1999 | 56 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Agios Pharmaceuticals | 540 |
| Lakefront Biotherapeutics NV | 452 |
| Kardigan | 241 |
| Stoke Therapeutics | 170 |
| Zenas BioPharma | 167 |
| Nanobiotix | 100 |
| Taysha Gene Therapies | 99 |
| GH Research | 73 |
SRPT News
- 11 days ago - Sarepta Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 11 days ago - Sarepta Therapeutics Quarterly report: Q2 2026 - Filings
- 11 days ago - Sarepta Therapeutics Earnings release: Q2 2026 - Filings
- 11 days ago - Sarepta Therapeutics Slides: Q2 2026 - Filings
- 11 days ago - Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments - Business Wire
- 18 days ago - Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 20 days ago - Sarepta names former Abbvie president as CEO as Ingram retires - Reuters
- 20 days ago - Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer - Business Wire